Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors - Archive ouverte HAL
Article Dans Une Revue Current Medicinal Chemistry Année : 2010

Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors

Résumé

The Pim (provirus insertion site of Moloney murine leukemia virus) family of serine/threonine protein kinases possesses the fundamental characteristics critical for the biology of eukaryotes, in particular, survival and malignant transformation of cells. The members of this protein family (Pim-1 to Pim-3) are aberrantly expressed in human tumors, most frequently in prostate cancer and hematological malignancies. Therefore, Pim proteins are widely considered as attractive targets in cancer chemotherapy. Growing knowledge of mechanisms of Pim-mediated anti-apoptosis and transformation, as well as rapid progress in the design of Pim-modulating compounds dictate the need for an in-depth analysis of the chemistry of inhibitors and the modes of their interaction with these protein kinases. This review summarizes recent advances in understanding the molecular events regulated by Pim proteins. In addition, we focus on the non-patent literature (mostly since 2005) that demonstrates a diversity of chemical classes of small molecular weight Pim inhibitors. The X-ray co-crystal structures of complexes Pim:inhibitor provide evidence for SAR data important for the choice of synthetic routes, optimization of lead compounds and testing chemical libraries. We also discuss a cell-based test system useful for rapid and inexpensive pre-screening of compounds capable of preventing Pim-mediated phosphorylation.

Dates et versions

hal-00538417 , version 1 (22-11-2010)

Identifiants

Citer

Fabrice Anizon, A. A. Shtil, V. N. Danilenko, Pascale Moreau. Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors. Current Medicinal Chemistry, 2010, 17 (34), pp.4114-4133. ⟨10.2174/092986710793348554⟩. ⟨hal-00538417⟩
47 Consultations
0 Téléchargements

Altmetric

Partager

More